Thanks for posting the MD&A Growacet. It seems that the trial completion projections announced at the AGM in September were a little overly optimistic (not too surprising). At the AGM, Resverlogix expected end of dosing and hitting 250 events to possibly occur by end of year. Now, in the MD&A is states H1 2019. That's quite a stretch. I would have liked to see a statement of Jan or Feb 2019, or even a general Q1 2019. They also previously stated at AGM that adjudication would take approximately 2 months trial completion. Now in the the MD&A it states 2-3 months for the adjudication period. Lastly, they previously stated at the AGM that top-line results would be announced "immediately" after adjudication. Now in the MD&A it states "shortly" thereafter. The bookends seem to have widened from AGM expectations. Perhaps more like 10 events per month instead of 10-15 events per month have been occurring since AGM. 

It will be interesting to see/hear what Resverlogix has to say at Biotech Showcase Jan 7-9. If these same MD&A statements are echoed at Biotech Showcase, then I find it highly unlikely that mid-March ACC 2019 is in play (kind of a long shot anyways). In the absence of a mid-March late breaking clinical trial ACC 2019 reveal of full data w/o top-line, look for the traditional top-line data sometime late Q1/early Q2 followed by presentation of full data at a major conference no earlier than May. I left one off of my previous list. European Atherosclerosis Society (EAS) 2019 May 26-29 in Maastricht, Netherlands should be added to that list. Enjoy the holidays everyone. Tick tock. 2019 is right around the corner. All just my opinion. DYODD.

BearDownAZ